Mumbai: Amidst the ever-changing and consistently evolving panorama of prescribed drugs, and medical gadgets, scientific analysis has change into an indispensable side in advancing medical effectivity. Nonetheless, this progress has ushered in elevated complexity in scientific research, requiring extremely structured and agile approaches.
The inaugural version of the ETPharma Medical Analysis Excellence Convention, themed ‘From Insights to Impression’ In Affiliation with Emmes, Affiliate Accomplice Adobe and Exhibit Accomplice Clarivate, strives to find the intersection of cutting-edge innovation, regulatory foresight, and operational excellence on the forefront of scientific analysis.
On the convention, numerous business consultants will share their insights into navigating the intricacies of up to date scientific analysis, addressing challenges and illuminating pivotal developments. Moreover, the convention will present a platform for individuals to unlock transformative avenues for achievement in scientific analysis.
The convention will begin with the opening remarks by ETPharma, adopted by a keynote deal with on ‘A Imaginative and prescient for Medical Analysis and Proof to 2030’ by the chief visitor, Dr Nilima Kshirsagar, Nationwide Chair, Medical Pharmacology, ICMR, India
The keynote deal with can be adopted by a presentation on ‘Medical Analysis & Innovation: Medical Perception is the Gateway’ by Dr Anil Pareek, President-Medical Affairs & Medical Analysis, Ipca Laboratories Restricted.
The presentation on ‘Medical Analysis & Innovation: Medical Perception is the Gateway’ can be adopted by one other presentation on ‘Powering twenty first Century Medical Analysis with Human and AI’ by Archana Sarda, Managing Director, EMMES India.
The ‘Powering twenty first Century Medical Analysis with Human and AI’ presentation can be adopted by a Trialogue on Strategic Harmonisation in Multinational Trials: Navigating Challenges and Seizing Alternatives. The individuals for the trialogue can be Dr Akhilesh Sharma, President and Chief Medical Officer, Alkem Laboratories Restricted; Dr Anil Kukreja, Vice President, Medical Affairs and Regulatory, AstraZeneca; and Dr Chirag Desai, Guide Medical Oncologist and Director, Hemato-Oncology Clinic, Vedanta. The session can be moderated by Dr Rajendra Jani, Impartial Topic Knowledgeable, Medical Analysis & Growth.
The trialogue can be adopted by a panel dialogue on ‘Decentralised Medical Trials or AI in Medical Trials’. The panellists for the session can be Dr Arani Chatterjee, Joint President, Cadila Prescribed drugs Ltd; Dr Subhash Thuluva, Senior VP & Head, Medical Growth & Pharmacovigilance, Organic E Ltd; Dr Vaibhav Salvi, Director and Head, Medical Research Unit, India and Southeast Asia, R&D-Medical Sciences and Operations, Sanofi; and Dr Shubhadeep Debabrata Sinha, Senior Vice President & Head (International), Medical Growth & Medical Affairs, Hetero Labs Restricted, would be the moderator for the dialogue.
The panel dialogue on ‘Decentralised Medical Trials or AI in Medical Trials?’ can be adopted by a presentation on Reworking Pharma: Streamlined Options with Adobe Doc Cloud by Mohd Yaman, Product & Resolution Knowledgeable, Adobe.
After Mohd Yaman’s presentation, a presentation on ‘Information-Pushed Acceleration and Predictive Paradigms in Medical Analysis and Growth’ can be adopted by Anuj Saini, Vice President & Head, Biopharmaceutics & Medical Growth, Zydus Lifesciences Ltd.
After Saini’s presentation, a panel dialogue on ‘A Multi-Stakeholder Perspective on Integrating Medical Analysis into the Continuum of Care’ will observe. The panellists for the dialogue can be Dr Avinash R Kakade, Sr Vice President International Head of Pharmacovigilance, Dr Reddy’s Laboratories; Dr Shubhadeep Debabrata Sinha, Senior Vice President & Head (International), Medical Growth & Medical Affairs, Hetero Labs Restricted; and Suneela Thatte, VP and Head, Healthcare R&D India, Merck Group. The session can be moderated by Dr Jaideep Gogtay, Chief Medical Officer, Cipla.
The dialogue on ‘A Multi-Stakeholder Perspective on Integrating Medical Analysis into the Continuum of Care’ can be adopted by a presentation on ‘Subsequent Gen Management & Way forward for Medical Growth’ by Kamala Rai, Vice President, Sr International Programme Head, International Well being Growth Unit, Novartis.
Rai’s presentation can be adopted by one other presentation on ‘Built-in Proof Era: Use of Actual-World Proof (RWE) in Product Growth’ by Dr Santosh Taur, Director Medical Affairs, Vaccines, Uncommon Ailments & Digital, Pfizer India Ltd.
The convention will conclude with a valedictory deal with on ‘Affected person Recruitment and Retention Technique within the Age of Decentralised Trials’ by Dr Sudipto Roy, Scientist ‘E’, Medical Research and Trials Unit (CSTU), Growth Analysis, Indian Council of Medical Analysis.
